<DOC>
	<DOCNO>NCT01149707</DOCNO>
	<brief_summary>PUR 0110 100 % natural novel investigational medicinal product demonstrate several vitro vivo pharmacology study potent anti-inflammatory , anti-oxidative immunomodulatory effect . This exploratory Phase 2a study first-in-patient study evaluate safety , tolerability , biomarker effect efficacy PUR 0110 rectal enema patient active mild-to-moderate distal ulcerative colitis ( UC ) . The study multicenter , randomize , double-blind , parallel-group , dose-ranging , placebo-controlled study . To eligible inclusion study , patient must either newly diagnose on-going active mild-to-moderate distal ulcerative colitis least 3 month duration confirm either case flexible sigmoidoscopy biopsy Screening Visit . In addition , patient must modify Mayo score ≥5 ≤10 include sigmoidoscopy inflammation grade rectal bleeding score ≥2 . Eligible patient randomly assign receive either PUR 0110 250 mg , 500 mg 1000 mg placebo rectal enema 1:1:1:1 ratio . Patients self-administer assigned study medication intrarectally once-daily bedtime ( 10:00 p.m +/- 1 hour ) 2 week . Patients evaluate safety adverse event , clinical laboratory test , vital sign , physical examination , electrocardiogram ( ECG ) , concomitant medication . Efficacy evaluation include modify Mayo score , patient-defined response remission , Investigator Assessment Ulcerative Colitis Symptom Score , Inflammatory Bowel Disease Questionnaire ( IBDQ ) , biomarkers inflammation , apoptosis total cell death , lipid peroxidation vivo oxidative stress , antioxidant defense mechanism plasma , serum , urine , feces biopsy tissue . Patients flexible sigmoidoscopy biopsy 12 hour last dose study medication .</brief_summary>
	<brief_title>Safety , Tolerability , Biomarker Efficacy Study PUR 0110 Rectal Enema Mild-to-Moderate Distal Ulcerative Colitis</brief_title>
	<detailed_description>Safety/Primary Outcome Parameters : - Incidence , nature severity adverse event - Incidence , nature severity clinical laboratory test abnormality Efficacy/Secondary Outcome Parameters : - Clinical remission define endoscopy score ≤ 1 , rectal bleeding score 0 , improvement change baseline stool frequency score end 2 week treatment / withdrawal visit ; - Clinical response rate define percentage patient drop ≥3 point baseline overall modify Mayo score ; - Patient define response remission rate ; - Change baseline overall modify Mayo score ( Disease Activity Index ) ; - Change baseline 4 individual sub-scores modify Mayo score ; - Change baseline Investigator Assessment UC Symptom Score ( total individual symptom score ) - Change baseline IBDQ score ( total 4 individual dimension score ) - Proportion patient treatment failure ; - Change baseline serum lutein level ; - Change baseline C-reactive protein ( CRP ) , high sensitivity CRP ( hs-CRP ) , erythrocyte sedimentation rate ( ESR ) , fecal calprotectin ( FCP ) , fecal lactoferrin ( FL ) . - Change baseline exploratory biomarkers include : serum interleukin-2 ( IL-2 ) , IL-6 , IL-8 , interferon-gamma ( IFN-gamma ) , tumor necrosis factor-alpha ( TNF-α ) , transform growth factor-beta ( TGF-beta ) , IL-4 , IL-10 , IL-17 , IL-23 , human beta-Defensin-2 ( hBD-2 ) , malondialdehyde ( MDA ) , lipoxin A4 ( LXA4 ) , glutathione ( GSH ) , M30 M65 apoptosomes serum biopsy , plasma urinary isoprostane level .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Proctocolitis</mesh_term>
	<criteria>1 . Outpatient male females 18 75 year . 2 . Females child bear potential must negative serum pregnancy test ( betahuman chorionic gonadotropin ) screening must sexually inactive ( abstinent ) 3 month prior dose throughout study use one follow acceptable method contraception : barrier method ( condom , diaphragm spermicide ) ; Intrauterine device ( IUD ) place least 3 month ; surgical sterilization partner ( vasectomy least 6 month ) ; hormonal contraceptive least 3 month prior dose . [ Female subject childbearing potential must advise remain sexually inactive maintain method contraception ≥7 day follow end dose study treatment ] 3 . Patients newly diagnose ongoing active distal ulcerative colitis &gt; 3 month duration , confirm flexible sigmoidoscopy screening , extend 5 50 cm anal margin . Sigmoidoscopy must conduct within 3 +/ 1 day Baseline ( Day 0 ) Visit . 4 . Patients ongoing active distal ulcerative colitis ≥3 month duration must stable dose oral mesalamine ( 5ASA ) ≥2 month Baseline ( Day 0 ) Visit . 5 . Modified Mayo Score ( Disease Activity Index ) ≥5 ≤10 Baseline , include sigmoidoscopic inflammation grade score ≥2 rectal bleed score ≥2 . 6 . Negative stool test screening rule parasite , bacterial pathogen Clostridium difficile . 7 . Able willing fill ( maintain ) daily diary card Day 7 Day 21 study . 8 . Able provide voluntary write informed consent prior initiation screening , must capable follow verbal write study instruction , able commit return visit entire period study . 1 . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatological , neurological , psychiatric disease , could compromise patient 's ability participate study , and/or interfere absorption study drug interpretation study data . 2 . Patients diagnosis Crohn 's disease . 3 . Patients modify Mayo score ≥11 Screening ( Day 7 &amp; Day 3 ) Visits . 4 . Patients immediate significant risk toxic megacolon ; bowel stricture , colonic dysplasia , adenoma carcinoma . 5 . Use botanical treatment supplement ulcerative colitis within 14 day prior Baseline Visit . 6 . Patients enteric pathogen , ova parasite , Clostridium difficile toxin stool . 7 . Female patient positive pregnancy test lactate Screening/Baseline Visits . 8 . History allergic reaction hypersensitivity spinach , spinach tablet , spinach powder spinach extract ; latex , mold mushroom . 9 . History gout , pseudogout hyperuricemia , kidney stone . 10 . History pseudoallergic hypersensitivity food color additive , tartrazine ( E102 ) , sunset yellow ( E110 ) FD &amp; C Blue No.1 ( Brilliant blue FCF ; E133 ) , allergic asthma , aspirin intolerance , severe multiple allergy . 11 . Past medical history significant gastrointestinal surgery include limited colostomy , ileostomy , previous colonic surgery appendectomy . 12 . Patients anatomical abnormality colon , e.g. , short bowel abnormality . 13 . Patients current infectious , ischemic , immunologic disease gastrointestinal involvement . 14 . Patients history failure retain enema . 15 . Use antibiotic reason related primary diagnosis gastrointestinalrelated condition within 14 day Baseline Visit . 16 . Patients use nonsteroidal antiinflammatory drug ( NSAIDs ) , include cyclooxygenase2 ( COX2 ) inhibitor , within 14 day prior Baseline Visit . Except aspirin ≤325 mg/day cardiovascular prophylaxis . 17 . Patients use follow medication use treat ulcerative colitis time indicated end Week 3 ( Visit 6 ) : Topical intrarectal corticosteroid topical intrarectal mesalamine within 14 day Baseline Visit ; Systemic corticosteroid ( oral injectable , include adrenocorticotropic hormone [ ACTH ] ) within 30 day Baseline Visit ; Immunosuppressant therapy ( methotrexate , azathioprine , 6mercatopurine cyclosporine ) within 60 day Baseline Visit ; Biologic therapy ( tumor necrosis factorα inhibitor , monoclonal antibody , etc . ) within 90 day Baseline Visit . 18 . Patients history active malignancy within past 5 year except squamous cell basal cell cancer skin . 19 . History clinical laboratory abnormality deem significant Principal Investigator . 20 . History significant alcohol drug abuse within one year prior Screening Visit . 21 . Patients test positive Screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) hepatitis C virus ( HCV ) . 22 . Exposure investigational nonregistered drug within 30 day prior administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>PUR 0110</keyword>
	<keyword>PUR 0110 Rectal Enema</keyword>
	<keyword>Distal Ulcerative Colitis</keyword>
	<keyword>Left-Sided Ulcerative Colitis</keyword>
	<keyword>Mild</keyword>
	<keyword>Moderate</keyword>
</DOC>